Selumetinib benefits children with inoperable plexiform neurofibromas
17 Apr 2020
byElaine Soliven
Treatment with selumetinib, an oral selective MEK inhibitor, leads to sustained reduction in neurofibroma volume and clinical benefit in children with neurofibromatosis type 1–inoperable plexiform neurofibromas, according to a recent study.
